
    
      After subjects have signed informed consent voluntarily, they go through screening period for
      within 28 days.

      As period I, subjects of Cohort1 take fimasartan and Amlodipine for 10 days and subjects of
      Cohort2 take rosuvastatin for 6 days.

      And then, as period II, subjects of both Cohorts take fimasartan, Amlodipine and rosuvastatin
      in Cohort1 case for 6 days and in Cohort2 case for 10 10days.

      For Fimasartan, subjects of Cohort1 have blood sampling 8th, 9th, 14th, 15th day before
      medication, 10th and 16th day before and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12 and
      24hour after medication(32 times in total).

      For Amlodipine, subjects of Cohort1 have blood sampling 8th, 9th, 14th, 15th day before
      medication, 10th and 16th day before and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 and 24hour after
      medication(30 times in total).

      For Rosuvastatin and N-desmethyl rosuvastatin, subjects of Cohort2 have blood sampling 4th,
      5th, 14th, 15th day before medication, 6th and 16th day before and 1, 2, 3, 4, 5, 6, 7, 8,
      10, 12 and 24hour after medication(28 times in total).
    
  